Top Markets
Coin of the day
Addex Therapeutics Ltd Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN
Rankning i aktier #33378
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase,... Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Aktiekurs
$0.05124204
Marknadsvärde
$7.78M
Förändring (1 dag)
0.51%
Förändring (1 år)
-23.73%
Land
CH
Handel Addex Therapeutics Ltd (ADXN)

Kategori

EPS för Addex Therapeutics Ltd (ADXN)
EPS per 2026 TTM: 0
Enligt Addex Therapeutics Ltds senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Addex Therapeutics Ltd från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter